Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B), while Vanguard Total World Stock Index Fund ETF trades at $159.15 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 44× Recursion Pharmaceuticals Inc's market cap, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| RXRX | VT | |
|---|---|---|
Market Cap | $2.31B | $101.70B |
Volume | 40,478,768 | 3,514,160 |
Sector | Health | Broad Market / Factor |
52-Week High | $6.79 | $162.39 |
52-Week Low | $2.84 | $134.19 |
Typical Hold Time | 22 Days | 53 Days |
Enterprise Value | $1.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Vanguard Total World Stock ETF (VT) trades at $159.64, down 0.66% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF maintains strong global diversification with over 9,700 holdings across developed and emerging markets. Recent news highlights VT's competitive positioning against peers like Schwab International Equity ETF and iShares MSCI World ETF, with analysts noting its comprehensive exposure and long-term performance advantages.
VT offers investors broad global equity exposure with low costs, though its expense ratio of 0.06% faces pressure from cheaper alternatives. The ETF's performance remains tied to global economic conditions, with risks including trade policy uncertainty and currency fluctuations. Analyst sentiment is generally positive for long-term diversification strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
